PJP:NYE-Invesco Dynamic Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 85.81

Change

-1.67 (-1.91)%

Market Cap

N/A

Volume

6.60K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-2.31 (-1.57%)

USD 40.46B
FHLC Fidelity® MSCI Health Care In..

-1.17 (-1.67%)

USD 2.91B
FXH First Trust Health Care AlphaD..

-2.16 (-1.94%)

USD 1.19B
XHE SPDR® S&P Health Care Equipme..

-1.78 (-1.96%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.66 (-2.70%)

USD 0.15B
SBIO ALPS Medical Breakthroughs ETF

-1.18 (-2.93%)

USD 0.13B
XHS SPDR® S&P Health Care Service..

-2.68 (-2.80%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.79 (-2.68%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-1.78 (-2.73%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.93 (-3.17%)

USD 0.01B

ETFs Containing PJP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.76% 90% A- 61% D-
Dividend Return 0.76% 56% F 11% F
Total Return 13.52% 90% A- 56% F
Trailing 12 Months  
Capital Gain 23.24% 67% D+ 65% D
Dividend Return 1.11% 56% F 12% F
Total Return 24.34% 67% D+ 61% D-
Trailing 5 Years  
Capital Gain 41.00% 76% C+ 67% D+
Dividend Return 5.68% 61% D- 14% F
Total Return 46.68% 71% C- 62% D
Average Annual (5 Year Horizon)  
Capital Gain 6.88% 76% C+ 58% F
Dividend Return 7.46% 71% C- 53% F
Total Return 0.57% 58% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 13.14% 76% C+ 71% C-
Risk Adjusted Return 56.72% 86% B+ 73% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike